Vaxcyte's Chief Technical Ops Officer Sells Shares [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year. Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte (NASDAQ:PCVX) , disposed of 9,743 shares in an open-market sale valued at approximately $454,891 according to the SEC Form 4 filing Metric Value Shares sold (direct) Transaction value ~$454,890.93 Post-transaction shares (direct) Post-transaction value (direct ownership) ~$1,111,694.88 Transaction value based on SEC Form 4 weighted average purchase price ($46.69); post-transaction value based on Jan. 2 market close ($46.46). How significant was this sale in relation to Dhaliwal's prior holdings? The transaction reduced direct ownership by 28.9%, shifting Dhaliwal's stake from 33,671 shares to 23,928 shares, with no remaining indirect exposure. Were any derivative, trust, or administrative mechanisms involved? This was a straightforward open-market sale of common s
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte (NASDAQ:PCVX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- What Makes Vaxcyte (PCVX) So Attractive [Yahoo! Finance]Yahoo! Finance
- How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- PCVX's page on the SEC website